Ipca Laboratories Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Ipca Laboratories Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹140Over the last 3 years, every ₹100 of reported profit came with ₹140 of operating cash.
Higher than 67% of Healthcare companies in India.
Self-Funding Ratio
1.8×Over the last 3 years its own operating cash covered its investment spending (capex) 1.8 times.
Higher than 65% of Healthcare companies in India.
Cash Locked Ratio
₹35For every ₹100 of sales, ₹35 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹31 tied up three years earlier.
More money tied up than 70% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹20Sales grew 54% in 3 years; of every extra ₹100 of sales, ₹20 became extra profit.
Higher than 58% of Healthcare companies in India.
Asset Productivity Ratio
+54% / +43%In 3 years sales changed by +54% while total assets changed by +43%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
1.9×Debt due within a year is covered 1.9 times by its yearly operating cash.
Higher than 59% of Healthcare companies in India.
Cash Cushion Ratio
+1%Cash, after subtracting all debt, equals 1% of its market value (net cash).
Higher than 64% of Healthcare companies in India.
Tangible Assets Ratio
98%Of every ₹100 the company owns, ₹98 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 55% of Healthcare companies in India.
Tangible Net Worth Ratio
98%Of every ₹100 of net worth, ₹98 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 56% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Ipca Laboratories Limited owes ₹0.23 for every ₹1 it owns. Net profit rose 55% in the year to Mar 2026, and grew 34% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
36.9Investors pay ₹36.9 for every ₹1 of Ipca Laboratories Limited's yearly profit, higher than 51% of Healthcare companies in India.
P/B ratio
5.99The share price is 5.99 times Ipca Laboratories Limited's book value per share, higher than 67% of Healthcare companies in India.
Market cap
₹48,293 CrThe total market value of all of Ipca Laboratories Limited's shares at today's price (share price × number of shares), larger than 88% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹8,064 CrWhat Ipca Laboratories Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹317.84Net worth divided by the number of shares. The share price of ₹1,904 is 6.0 times this, which is the P/B above.
Return on equity (ROE)
16.2%Ipca Laboratories Limited earned 16.2% on its shareholders' money over the last year, higher than 62% of Healthcare companies in India.
Owes vs Owns
0.23×Ipca Laboratories Limited owes ₹0.23 for every ₹1 it owns (low), lower than 78% of Healthcare companies in India.
Dividend yield
0.31%Ipca Laboratories Limited pays 0.31% of its share price as dividends a year, lower than 58% of dividend-paying Healthcare companies in India.
Revenue growth
+8%Revenue rose 8% in the year to Mar 2026, and grew 15% a year on average over 3 years.
Profit growth
+55%Net profit rose 55% in the year to Mar 2026, and grew 34% a year on average over 3 years.
Profit margin
11.9%Ipca Laboratories Limited keeps ₹12 of every ₹100 of revenue as net profit.
Cash quality
1.00×Cash from Ipca Laboratories Limited's business was 1.00× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
21.5×Ipca Laboratories Limited's operating profit covered its interest costs 21.5 times in the year to Mar 2026.
Cash vs debt
Net cashIpca Laboratories Limited held ₹387 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Ipca Laboratories Limited's P/E ratio?
Investors pay ₹36.9 for every ₹1 of Ipca Laboratories Limited's yearly profit, higher than 51% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Ipca Laboratories Limited: ₹48,293 Cr ÷ ₹8,064 Cr (31 Mar 2026) = 6.0.
What is Ipca Laboratories Limited's return on equity?
Ipca Laboratories Limited earned 16.2% on its shareholders' money over the last year, higher than 62% of Healthcare companies in India.
How much does Ipca Laboratories Limited owe compared with what it owns?
Ipca Laboratories Limited owes ₹0.23 for every ₹1 it owns (low), lower than 78% of Healthcare companies in India.
Does Ipca Laboratories Limited pay a dividend?
Yes. Ipca Laboratories Limited pays 0.31% of its share price as dividends a year, lower than 58% of dividend-paying Healthcare companies in India.
Is Ipca Laboratories Limited's revenue growing?
Revenue rose 8% in the year to Mar 2026, and grew 15% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.